Communiqués Kalaris Therapeutics, Inc.

Actions

KLRS

US4829291065

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:25:08 07/10/2026			Varia. 5j.	Varia. 1 janv.
2,670 ^USD	+0,38%		-8,28%	-68,48%

11/08	Kalaris Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/07	Kalaris Therapeutics nomme Liisa Bayko au poste de directrice financière	MT

Communiqués

31/08	Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference	AQ
11/08	Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
20/07	Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer	AQ
17/07	Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts	AQ
06/07	Kalaris Appoints Laurie Keating to Board of Directors	AQ
23/06	Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling	AQ
12/06	Kalaris to Present at Clinical Trials at the Summit 2026	AQ
12/05	Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
17/03	Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates	AQ
28/01	Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting	AQ
17/12	Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement	AQ
17/12	Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD	AQ
24/11	Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference	NE
12/11	Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates	AQ
03/11	Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer	AQ
30/10/25	Kalaris to Present at Stifel 2025 Annual Healthcare Conference	AQ
15/09/25	Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration	AQ
13/08/25	Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates	AQ
02/06/25	Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference	AQ
23/05/25	Kalaris to Participate at Stifel Ophthalmology Forum	AQ
14/05/25	Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights	AQ
04/04/25	Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee	AQ